Material Event (Form 8-K)

Item 8.01 Other Events

On May 15, 2025, Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) announced the identification of Telomir-Ag2 as a novel drug candidate following successful preclinical validation of its antimicrobial activity. Telomir-Ag2 is a stabilized Silver(II) complex developed using the Company's proprietary Telomir-1 platform.

In a recent Minimum Inhibitory Concentration (MIC) study, Telomir-Ag2 demonstrated broad-spectrum antibacterial activity against both Gram-positive and Gram-negative strains, including methicillin- and aminoglycoside-resistant Staphylococcus aureus (MARSA). Telomir-Ag2 also showed greater antibacterial activity compared to the Company's Silver(I)-based formulation, Telomir-Ag1.

This development builds on the Company's previously announced scientific achievement in stabilizing Silver(II) in a biologically compatible form. Silver(II) is known for its high oxidative potential and potent antimicrobial properties but has historically been considered too unstable for use in medicine. The ability to stabilize and preserve its activity represents a notable advancement in the field of antimicrobial science.

The Company believes these results may have potential implications for addressing drug-resistant infections in high-risk settings, such as burn wounds and post-surgical complications. Telomir plans to proceed with formulation development and evaluate strategic and regulatory pathways to advance Telomir-Ag2.

For additional details, please refer to the press release issued on May 15, 2025, available on the Company's website at www.telomirpharma.com.